[Breast cancer prognosis in Salah Azaiez Institute of Cancer, Tunis]
AbstractWe estimated survival rate at 9 years of all  women with breast cancer diagnosed at Salah Aza‹ez Institute of Cancer in Tunis to identify the main prognosis factors. Data were collected on residence, socioeconomic level, circumstances of discovery of the tumour, histological type, tumour size, presence of metastases, extension of the tumour, treatment and survival. Comparison of survival curves was done with Log Rank test. Cox model was used for multivariate adjustments and calculation of the hazard ratio [HR] [relative risk of death]. There was a survival rate of 61% at 5 years and of 51% at 9 years. Tumour size > 5 cm was significantly associated with lower survival as was capsular rupture. After stratification for tumour size and age, only surgery and radiotherapy were significantly associated with improved survival
Ben Gobrane, H., Fakhfakh, R., Rahal, K., Ben Ayed, F., Maalej, M. et al. (2007). [Breast cancer prognosis in Salah Azaiez Institute of Cancer, Tunis]. http://www.who.int/iris/handle/10665/117253
EMHJ - Eastern Mediterranean Health Journal, 13 (2), 309-318, 2007
MetadataShow full item record
Showing items related by title and MeSH subject.
Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry Sadjadi, A.; Nouraie, M.; Ghorbani, A.; Alimohammadian, M.; Malekzadeh, R. (2009)This study presents the first population-based report on breast cancer in the Islamic Republic of Iran using data derived from a cancer registry. A retrospective study was conducted to find all new breast cancer cases in 5 provinces covered by the cancer registry during the 5-year period 1996-2000. There were 2421 cases recorded in the 5 registries. The age-standardized incidence rate [ASR] was 16.2 per 100 000 person-years. In contrast to more developed countries, the ASR of breast cancer was low, with the lowest rate seen in Ardabil province
Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients Bahrami, A.; Mortazavizadeh, M.R.; Yazdi, M.F.; Chamani, M. (2012)The value of serum tumour markers in the prognosis of patients with breast cancer is controversial. This prospective study in Yazd, Islamic Republic of Iran, assessed the value of the tumour markers carcinoembryonic antigen [CEA] and cancer antigen [CA] 15-3 in 159 patients with primary breast cancer. CEA and CA15-3 assays [mean 14 per patient] were performed at diagnosis, end of surgery and chemotherapy and every 3 months in the first 2 years and every 6 months in second 2 years of the follow-up period. During follow-up, 33 patients [20.8%] ...
Miller, Anthony B (1992)